22 results on '"Ock, C-Y."'
Search Results
2. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
3. 94P Performance validation of an artificial intelligence-powered programmed death-ligand 1 (PD-L1) combined positive score analyzer in urothelial cancer
4. 1706P Artificial intelligence-powered tumor purity assessment from H&E whole slide images associates with variant allele frequency of somatic mutations across 23 cancer types in TCGA cohorts
5. 1704P Multimodal approach to discover novel targets for antibody-drug conjugates by analyzing distinct expression patterns of frequent copy number aberration
6. 155P Artificial Intelligence (AI) - powered human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TIL) analysis for HER2-positive early breast cancer patients treated with HER2-targeted neoadjuvant chemotherapy (NAC)
7. 900P AI-powered analyzer reveals enrichment of intra-tumoral tumor-infiltrating lymphocytes in high-grade neuroendocrine neoplasms
8. 1411P AI-powered immune phenotype predicts favorable outcomes of nivolumab (niv) plus chemotherapy (chemo) in advanced fgastric cancer (AGC): A multi-center real-world data analysis
9. 398P AI-powered whole-slide image analysis of tumor-infiltrating lymphocytes for prediction of prognosis in colorectal cancer
10. 1805P Assistance with an artificial intelligence-powered PD-L1 analyzer reduces interobserver variation in pathologic reading of tumor proportion score in non-small cell lung cancer
11. 977P Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
12. 270P Phase Ib study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer
13. 2330P Pre-test prediction of multiple druggable mutations based on H&E image artificial intelligence (AI) analysis may enable more efficient clinical workflow for treatment decisions in non-small cell lung cancer (NSCLC)
14. 874P Artificial intelligence (AI)-powered spatial tumor-infiltrating lymphocyte (TIL) analysis in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitor (ICI) treatment
15. 571P Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial
16. 569P Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
17. 118P Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-1 in advanced biliary tract cancer (BTC)
18. 1453P Safety and efficacy of vactosertib, a TGF-βR1 kinase inhibitor, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma
19. Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
20. 1529P - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
21. 355O Artificial intelligence-powered spatial analysis of tumor microenvironment (TME) in nasopharyngeal carcinoma (NPC) patients treated with immune checkpoint inhibitors (ICI).
22. Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.